Re-Registration

WORKSHOP 1: Diagnostic Approach of Elevated Transaminase
Case Study (Open for Participant): DILI Hepatocellular, MASLD, Congestive liver, Autoimmune Hepatitis, Hypoxic Hepatitis

Speaker: Muhammad Yusuf Hanif
Panelist: Andri Sanityoso Sulaiman & Muhammad Yusuf Hanif

WORKSHOP 2: Diagnostic Approach of Hiperbilirubinemia
• Case study (Open for Participant): Septic cholestasis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Advanced Liver Disease, Obstructive Jaundice

Speaker: Pitt Akbar
Panelist: Irsan Hasan & Pitt Akbar

WORKSHOP 3: Update Management of Hepatitis B
• Case study (Open for Participant): Treated, Not Treated, Prophylaxis before immunosuppresive, HCC related Hep B, Pregnancy

Speaker: Kemal Fariz Kalista
Panelist: Juferdy Kurniawan & Kemal Fariz Kalista

WORKSHOP 4: POCUS in HPB Disease (Hands-On in Real Pathologic Case)

Speaker: Andri Sanityoso Sulaiman
Fasilitator: Kemal Fariz Kalista, Yaditta Mirdania & Pitt Akbar

Re-Registration

SESSION 1 - Early Diagnosis and Preventing Complication in Advance Liver Disease – Case-Based Study
• Non Invasive Assessment for Liver Fibrosis in Primary Care: When to Refer - Imelda Maria Loho
• Redefining Acid Suppression in Liver Cirrhosis: Can P-CAB Prevent Liver Related Event? - Andri Sanityoso Sulaiman
• Q&A

SESSION 2 - Grand Round Expert – Lecture
• HCC - Irsan Hasan
• ACLF - Rino Alvani Gani
• Liver Cirrhosis - Andri Sanityoso Sulaeman
• MASLD - Chyntia Olivia M. Jasirwan
• Q&A

SESSION 3 - Beyond tumor response : Navigating Treatment Decision for Long term disease control in uHCC – Case-Based Study
• Dual IO Approach in First Line Treatment of uHCC: Who and What? - Cosmas Rinaldi A. Lesmana
• Navigating Bleeding Risk Assessment for Optimal Long Term Disease Control - Imelda Maria Loho
• Q&A

SESSION 4 - MASLD Beyond the Gray: Consensus Controversies and Emerging Frontiers - Lecture
Moderator : Saut Horas H. Nababan

• Into the Gray Areas: Polling the Controversial Points in the MASLD Consensus - Chyntia Olivia M. Jasirwan
• The Emerging Role of Endoscopic Bariatric Therapy in MASH: Beyond Weight Loss - Cosmas Rinaldi A. Lesmana
• Q&A

SESSION 5 - Strategy to Improve Survival in Acute-on-Chronic Liver Failure – Case-Based Study
• Steroid in HBV associated ACLF - Rino Alvani Gani
• Clinical implication of type A and type B ACLF - Kemal Fariz Kalista
• Q&A

SESSION 6 - Hepatitis B Update Guideline – Lecture
• The Updated 2026 Indonesian Hepatitis B Consensus: Practice-Changing Updates for Everyday Clinical Care - Juferdy Kurniawan
• Q&A

Re-Registration

Session 7 - Grand Round Expert – Lecture
• Autoimmune Liver Disease - Saut Horas H. Nababan
• Living Donor Liver Transplantation - Kemal Fariz Kalista
• Hepatitis B - Juferdy Kurniawan
• Living Donor Selection - Pitt Akbar
• Q&A

SESSION 8 - IO-VEGF as cornerstone in systemic therapy for uHCC: What should we know? – Lecture
Moderator : Saut Horas H. Nababan

• Maximizing the ORR and Improving Long-Term OS: Atezo-Bev as 1L systemic therapy for uHCC - Lianda Siregar
• Strike While the Iron Is Hot: Managing the Golden Window of Response in Atezo-Bev - Irsan Hasan
• Q&A

SESSION 9 - Rethinking the HCC Patient Journey: From Early Recurrence to Disease Control and Supportive Care – Lecture
Moderator : Kemal Fariz Kalista

• Early Recurrence in HCC: Recognizing Aggressive Disease and Navigating the Next Treatment Decision - Lianda Siregar
• Constipation in Patients with Cancer: Clinical Challenges and the Role of Bile Acid Modulation - Irsan Hasan
• Q&A

SESSION 10 - Non Invasive Test Monitoring for Chronic Liver Disease- Lecture
Moderator : Andri Sanityoso Sulaiman

• Clinical Utility of HBsAg Levels: Monitoring Viral Suppression and Its Impact on Parenchymal Preservation - Saut Horas H Nababan
• M2BPGi Serum Levels: Predicting Fibrosis Progression and Long-Term Liver Outcomes - Cosmas Rinaldi A. Lesmana
• Q&A

SESSION 11 - Precision HCC Imaging: How EOB-MRI Shapes Diagnosis, Prognosis and Treatment– Lecture
Moderator : Chyntia Olivia M. Jasirwan

• HCC Surveillance for Early Detection: Optimizing Imaging Strategies in High Risk Patients - HCC Surveillance for Early Detection: Optimizing Strategies in High Risk Patients - Juferdy Kurniawan
• Gadoxetic Acid-Enhanced MRI: When Imaging Changes the Management of Liver Lesions - Sahat Basana Romanti Ezer Matondang
• Q&A

SESSION 12 - 16 years Experience of Living Donor Liver Transplantation in Cipto Hospital – Lecture
• Living Donor Selection, Experience of 103 LDLT Cases - Kemal Fariz Kalista
• Post Hepatectomy Complication, Experience of 103 LDLT Case - Arnetta Naomi Louise Lalisang
• Q&A